Skip to main content
. 2012 May 17;13(5):401–406. doi: 10.1007/s10194-012-0455-4

Fig. 2.

Fig. 2

Changes in migraine intensity from baseline during treatment with frovatriptan (continuous line) or almotriptan (dashed line) in the 67 women with menstrually related migraine included in this analysis. The asterisks refer to the statistical significance of the between-treatment difference (*p < 0.05)